All In Biotech

Drug Trial Radar · NCT06800313

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

Phase 1/2 Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

190

Planned (sponsor's estimate)

Start

Feb 6, 2025

Primary completion

Aug 17, 2028

Study completion Aug 17, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

Conditions

  • Metastatic Prostate Cancer

Interventions

  • JNJ-101556143 Formulation 1Drug

    Experimental: Oral JNJ-101556143

  • JNJ-101556143 Formulation 2Drug

    Experimental: Oral JNJ-101556143

  • JNJ-101556143 Formulation 3Drug

    Experimental: Oral JNJ-101556143

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of dose-limiting toxicities (DLTs)Time frame: 21 days
  2. Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baselineTime frame: 21 days
  3. Phase 1 Part 2 (formulation exploration) relative bioavailabilityTime frame: 22 days

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • Rocky Mountain Cancer Center

    Colorado Springs, Colorado · Recruiting

  • Sarah Cannon Research Institute 1

    Denver, Colorado · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • XCancer Research Network LCMC Health EJGH

    Metairie, Louisiana · Recruiting

  • Dana Farber Mass General Brigham Cancer Care Inc

    Boston, Massachusetts · Recruiting

  • South Texas Accelerated Research Therapeutics, LLC (START)

    Grand Rapids, Michigan · Recruiting

  • Urology Cancer Center, PC

    Omaha, Nebraska · Recruiting

  • Memorial Sloan Kettering Cancer Center

    Long Island City, New York · Recruiting

  • Associated Medical Professionals

    Syracuse, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • Urology Associates

    Nashville, Tennessee · Recruiting

  • NEXT Oncology

    Austin, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Virginia Clinical Research

    Norfolk, Virginia · Recruiting

  • The Royal Marsden NHS Trust

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.